DeepMed Research

Tilmanocept

Generic Name: Tilmanocept

Brand Names: Lymphoseek

Drug Type: Small Molecule

CAS Number: 1185986-76-8

Unique Ingredient Identifier: MDU8BQ474H

Background: Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).

Associated Conditions: Breast Cancer, Melanoma, Oral Cancer

Clinical Trials

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tc99m tilmanocept

First Posted Date: 2021-07-01

Last Posted Date: 2025-01-08

Lead Sponsor: Navidea Biopharmaceuticals

Target Recruit Count: 134

Registration Number: NCT04947137

Locations: 🇺🇸
Innovation Medical Research Center, Palmetto Bay, Florida, United States
🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸
Sun Research Institute, San Antonio, Texas, United States

and more 4 locations

Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma

Early Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Tc-99m tilmanocept

First Posted Date: 2020-12-10

Last Posted Date: 2023-12-13

Lead Sponsor: John O. Prior

Target Recruit Count: 5

Registration Number: NCT04663126

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland

Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Cancer

Interventions: Drug: Lymphoseek
Device: Single Photon Emission Computed Tomography (SPECT)
Drug: Indocyanine Green (ICG)
Device: Neoprobe Gamma Detection System NPB11L(Model1102)

First Posted Date: 2020-08-12

Last Posted Date: 2023-10-11

Lead Sponsor: Stanford University

Target Recruit Count: 6

Registration Number: NCT04511026

Locations: 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States

Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer

Phase 4

Withdrawn

Conditions: Breast Cancer
Sentinel Lymph Node

Interventions: Drug: Tilmanocept
Drug: Nanocolloid

First Posted Date: 2020-07-27

Last Posted Date: 2021-05-14

Lead Sponsor: University Hospital, Ghent

Registration Number: NCT04487912

Locations: 🇧🇪
university hospital, Ghent, Gent, Belgium

Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer

Phase 4

Conditions: Head Cancer
Melanoma
Breast Cancer
Neck Cancer

Interventions: Drug: Lymphoseek
Drug: Nanocoll

First Posted Date: 2020-02-07

Last Posted Date: 2020-02-20

Lead Sponsor: Anna Cruceta

Target Recruit Count: 30

Registration Number: NCT04261179

Locations: 🇪🇸
Hospital Clínico y provincial de Barcelona, Barcelona, Spain

Mapping Draining Lymph Nodes in CNS Malignancies

Phase 1

Terminated

Conditions: Central Nervous System Tumor
Central Nervous System Neoplasms

Interventions: Drug: Tc-99m tilmanocept

First Posted Date: 2019-09-20

Last Posted Date: 2023-12-21

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 14

Registration Number: NCT04096716

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tc 99m tilmanocept

First Posted Date: 2019-09-04

Last Posted Date: 2025-01-08

Lead Sponsor: Navidea Biopharmaceuticals

Target Recruit Count: 20

Registration Number: NCT04078191

Locations: 🇬🇧
Royal Free Hospital, London, England, United Kingdom
🇬🇧
Barts Hospital, London, England, United Kingdom
🇺🇸
Attune Health, Beverly Hills, California, United States

and more 1 locations

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tc 99m tilmanocept

First Posted Date: 2019-05-06

Last Posted Date: 2023-08-24

Lead Sponsor: Navidea Biopharmaceuticals

Target Recruit Count: 116

Registration Number: NCT03938636

Locations: 🇺🇸
Central States Research, Tulsa, Oklahoma, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 7 locations

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Head and Neck Cancer

Interventions: Drug: Panitumumab-IRDye800
Drug: Lymphoseek

First Posted Date: 2018-01-19

Last Posted Date: 2022-11-10

Lead Sponsor: Eben Rosenthal

Target Recruit Count: 3

Registration Number: NCT03405142

Locations: 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States

Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

Phase 1

Withdrawn

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Tilmanocept

First Posted Date: 2017-08-07

Last Posted Date: 2018-10-09

Lead Sponsor: Navidea Biopharmaceuticals

Registration Number: NCT03241446

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy